Android app on Google Play

StreetInsider.com Pre-Open Movers 02/05: (OPXA) (PLX) (VMED) Higher; (HEB) (YUM) (JCP) Lower (more...)

February 5, 2013 9:41 AM EST Send to a Friend
Get Alerts OPXA Hot Sheet
Trade OPXA Now!
Join SI Premium – FREE
Opexa Therapeutics, Inc. (NASDAQ: OPXA) 300% HIGHER; announced the execution of an agreement with Merck Serono, a division of Merck, Darmstadt, Germany, for the development and commercialization of Tcelna (imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Tcelna (imilecleucel-T) is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS (SPMS). Potential payments to Opexa from the option and license agreement could total $225 million based upon the successful development and commercialization of Tcelna for MS.

Hemispherx Biopharma, Inc. (NYSE: HEB) 34% LOWER; announced that it received a Complete Response Letter from the US Food and Drug Administration ("FDA") declining to approve its new drug application ("NDA") for Ampligen® for Chronic Fatigue Syndrome ("CFS"). The FDA said Hemispherx should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses.

Protalix BioTherapeutics, Inc. (NYSE: PLX) 19% HIGHER; speculation Pfizer could buy the company.

Virgin Media Inc. (NASDAQ: VMED) 15% HIGHER; notes the recent press speculation in relation to a possible corporate transaction between Virgin Media Inc. and Liberty Global, Inc. (NASDAQ: LBTYA). Virgin Media confirms that it is in discussions with Liberty Global, Inc., a leading international cable company, concerning a possible transaction. Any such transaction would be subject to regulatory and other conditions.

NII Holdings, Inc. (Nasdaq: NIHD) 12% LOWER; announced its preliminary consolidated financial results for the fourth quarter and full year 2012. For the fourth quarter, the Company expects to report consolidated operating revenues of approximately $1.5 billion, net subscriber additions of approximately 2,200, and total capital expenditures of approximately $525 million.*** The Street is at revs of $1.47 billion.

ARM Holdings plc (NASDAQ: ARMH) 8% HIGHER; Q4 results, outlook

Repros Therapeutics (NASDAQ: RPRX) 7% HIGHER Lazard Capital initiates coverage on with a Buy. PT $26.00.

Yum! Brands, Inc. (NYSE: YUM) 7% LOWER; Reported Q4 EPS of $0.83, $0.01 better than the analyst estimate of $0.82. Revenue for the quarter came in at $4.15 billion versus the consensus estimate of $4.12 billion. The company estimates a mid-single digit EPS decline in 2013 versus prior year, excluding Special Items.

Thor Industries, Inc. (NYSE: THO) 5% HIGHER; announced preliminary sales, backlog and cash, cash equivalents and investments for the second quarter and six months ended January 31, 2013. Preliminary consolidated sales in the second quarter were $741.4 million, up 24.2% from $597.0 million in the second quarter last year. RV sales were $636.1 million, up 27.0% from $501.0 million in last year's second quarter. Towable RV sales for the second quarter were $522.4 million, up 17.6% from $444.2 million in the second quarter of fiscal 2012. Motorized RV sales in the second quarter more than doubled to $113.7 million from $56.8 million in the same quarter a year ago. Bus sales were $105.3 million, up 9.7% from $96.0 million in the second quarter last year. *** The Street sees Q2 sales of $715.7 million

J.C. Penney Co., Inc. (NYSE: JCP) 5% LOWER; received a letter dated January 29, 2013 from Brown Rudnick LLP claiming to represent holders of more than 50% of the Company`s 7.4% Debentures due 2037. The letter purports to be a Notice of Default under the Indenture for these Debentures dated April 1, 1994 between J. C. Penney Company, Inc. and U. S. Bank National Association as trustee. The Company strongly believes the Notice of Default is invalid and utterly without merit.

Baidu.com (NASDAQ: BIDU) 5% LOWER; reported Q4 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion. Baidu.com sees Q1 2013 revenue of $945.4-975.9 million, versus the consensus of $967.1 million.

Arch Coal, Inc. (NYSE: ACI) 4% LOWER; reported Q4 EPS of ($0.42), $0.27 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $968.2 million versus the consensus estimate of $997.55 million.

Bed Bath & Beyond (NASDAQ: BBBY) 4% HIGHER; Citi upgraded from Neutral to Buy.

Vanda Pharmaceuticals (NASDAQ: VNDA) 4% HIGHER; Lazard Capital initiates coverage with a Buy. PT $11.00

Celldex Therapeutics, Inc. (Nasdaq: CLDX) 4% LOWER; announced that it is offering $75,000,000 of its common stock in a proposed underwritten public offering.

Hologic, Inc. (NASDAQ: HOLX) 4% LOWER; reported Q1 EPS of $0.38, in-line with the analyst estimate of $0.38. Revenue for the quarter came in at $631.4 million versus the consensus estimate of $646.52 million. Hologic, Inc. sees FY2013 revenue of $2.61-2.64 billion, versus the consensus of $2.64 billion. sees FY2013 EPS of $1.58 to $1.60, versus the consensus of $1.58. Hologic, Inc. sees Q2 2013 revenue of $635-640 million, versus the consensus of $650.23 million. Sees EPS of $0.33-$0.34 versus the consensus of $0.38.

HCA Holdings (NYSE: HCA) 3% LOWER; reported Q4 EPS of $0.92, ex-items, $0.09 better than the analyst estimate of $0.83. Revenue for the quarter came in at $8.43 billion versus the consensus estimate of $8.95 billion. HCA Holdings sees FY2013 EPS of $3.00-3.30, versus the consensus of $3.46. HCA Holdings sees FY2013 revenue of $33.5-34.5 billion, versus the consensus of $37.52 billion.

KCAP Financial, Inc. (Nasdaq: KCAP) 3% LOWER; commenced a public offering of 4,000,000 shares of its common stock. KCAP intends to use the net proceeds of this public offering for general corporate purposes, which includes investing in portfolio companies and collateralized loan obligation funds in accordance with its investment objective and strategies.

Estee Lauder Cos., Inc. (NYSE: EL) 3% HIGHER; reported Q2 EPS of $1.16, $0.11 better than the analyst estimate of $1.05. Revenue for the quarter came in at $2.93 billion versus the consensus estimate of $2.9 billion. Estee Lauder Cos., Inc. sees Q3 2013 EPS of $0.28-0.32, versus the consensus of $0.47. Estee Lauder Cos., Inc. sees FY2013 EPS of $2.51-2.59, versus the consensus of $2.57

Cigna Corporation (NYSE: CI) 3% HIGHER; announced a definitive agreement with Berkshire Hathaway Life Insurance Company of Nebraska, a member of the Berkshire Hathaway, Inc. (NYSE: BRK-A) (NYSE: BRK-B) group (Berkshire), under which Berkshire will reinsure Cigna's Run-off Guaranteed Minimum Death Benefits (VADBe) and Guaranteed Minimum Income Benefits (GMIB) businesses effective February 4, 2013. Cigna will fund this transaction with an incremental $100 million of parent company cash, approximately $1.8 billion of investment assets supporting the run-off businesses, and an estimated $300 million tax benefit associated with the transaction.

Advanced Energy Industries, Inc. (NASDAQ: AEIS) 3% HIGHER; reported Q4 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $113 million versus the consensus estimate of $111.43 million. Advanced Energy Industries, Inc. sees Q1 2013 EPS of $0.14-0.18, versus the consensus of $0.11. Advanced Energy Industries, Inc. sees Q1 2013 revenue of $105-115 million, versus the consensus of $100.64 million.

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 3% LOWER; announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.

UnitedHealth Group (NYSE: UNH) 2% HIGHER; Goldman Sachs upgraded from Neutral to CL Buy with a price target of $66.00 (from $57.00)

SandRidge Energy, Inc. (NYSE: SD) 2% LOWER; JPMorgan downgraded SandRidge Energy (NYSE: SD) from Neutral to Underweight with a price target of $5.00 (from $9.50).

Solarwinds (NYSE: SWI) 1% HIGHER; reported Q4 EPS of $0.36, $0.03 better than the analyst estimate of $0.33. Revenue for the quarter came in at $73.5 million versus the consensus estimate of $70.72 million. Solarwinds sees FY2013 revenue of $330-338 million, versus the consensus of $331.54 million. Sees FY2013 EPS of $1.57-$1.62, versus the consensus of $1.54. Solarwinds sees FY2013 revenue of $74.9-75.7 million, versus the consensus of $74.64 million. Sees Q4 EPS of $0.36, versus the consensus of $0.35.

Gilead Sciences, Inc. (NASDAQ: GILD) 1% HIGHER; reported Q4 EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.43 billion.

AK Steel Holding Corporation (NYSE: AKS) 1% HIGHER; CRT Capital upgraded AK Steel from Fairly Valued to Buy with a price target of $6.00.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Warren Buffett, JPMorgan, Citi, Lazard, Earnings

Add Your Comment